SYROS PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Continuing Operations
SYROS PHARMACEUTICALS, INC. reported Net Cash Provided by (Used in) Continuing Operations of -$16.44 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2017-11-08
- SYROS PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for the quarter ending 2017-09-30 was -$37.38M, a 186.18% decline year-over-year.
- SYROS PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for the quarter ending 2017-06-30 was $31.53M.
- SYROS PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for the quarter ending 2017-03-31 was -$10.59M, a 140.38% decline year-over-year.
- SYROS PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for the quarter ending 2016-12-31 was -$34.91M.
- SYROS PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for fiscal 2016 was $22.68M.
- SYROS PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for fiscal 2015 was -$24.48M, a 143.26% decline from fiscal 2014.
- SYROS PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for fiscal 2014 was $56.59M.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-09-30 | -$37.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$5.85M derived: sum of 2 quarters · filed 2017-11-08 | -$16.44M 10-Q · filed 2017-11-08 | -$51.34M derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-06-30 | $31.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $20.94M 10-Q · filed 2017-08-09 | -$13.96M derived: sum of 3 quarters · filed 2017-08-09 | $29.41M derived: sum of 4 quarters · filed 2017-11-08 |
| 2017-03-31 | -$10.59M 10-Q · filed 2017-05-15 | -$45.49M derived: sum of 2 quarters · filed 2017-05-15 | -$2.12M derived: sum of 3 quarters · filed 2017-11-08 | -$14.13M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-12-31 | -$34.91M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-20 | $8.47M derived: sum of 2 quarters · filed 2017-11-08 | -$3.54M derived: sum of 3 quarters · filed 2017-11-08 | $22.68M 10-K · filed 2017-03-20 |
| 2016-09-30 | $43.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $31.36M derived: sum of 2 quarters · filed 2017-11-08 | $57.59M 10-Q · filed 2017-11-08 | $48.51M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | -$12.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $14.21M 10-Q · filed 2017-08-09 | $5.13M derived: sum of 3 quarters · filed 2017-08-09 | -$1.06M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $26.22M 10-Q · filed 2017-05-15 | $17.15M derived: sum of 2 quarters · filed 2017-05-15 | $10.96M derived: sum of 3 quarters · filed 2017-05-15 | |
| 2015-12-31 | -$9.08M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-20 | -$15.27M derived: sum of 2 quarters · filed 2017-03-20 | -$24.48M 10-K · filed 2017-03-20 | |
| 2015-09-30 | -$6.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$15.41M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | -$9.22M 10-Q · filed 2016-08-15 | |||
| 2014-12-31 | $56.59M 10-K · filed 2017-03-20 |